INS and metabolic dysfunction-associated steatohepatitis: Compared to the T2DM-NASH group, celecoxib significantly reduced insulin levels and HOMA-IR and increased ISI in the T2DM-NASH-Cele group (Table 2; Fig. 1A and B).